Dr Suh and colleagues from New Jersey estimated the relative risk for ischemic colitis in patients with and without irritable bowel syndrome (IBS) or constipation.
The research team evaluated the role of IBS and constipation in commonly used gastrointestinal medications and ischemic colitis.
The team identified patient cohorts with the use of longitudinal MarketScan research databases from 1999 to 2002.
Patients in each study cohort were matched with comparable control patients using a propensity score.
The team used a Cox proportional hazards models to estimate relative risk for ischemic colitis.
|The relative risk for ischemic colitis was 3 times higher with IBS|
|Alimentary Pharmacology and Therapeutics|
The researchers found that the relative risk for ischemic colitis was 3 times higher for patients with IBS and constipation.
Patients who were taking an antispasmodic, a proton pump inhibitor, or an H2-antagonist were at increased risk for ischemic colitis.
However, when the researchers adjusted these results for IBS or constipation, the relative risks were attenuated and no longer statistically significant.
Dr Suh's team concluded, “Patients with IBS or constipation demonstrated a 2- to 3-fold increased risk for ischemic colitis.”
“Moreover, IBS and constipation strongly confounded the relationship between gastrointestinal drug use and the risk for ischemic colitis.”
“This suggests that etiologic studies of ischemic colitis risk must account for the presence of irritable bowel syndrome or constipation.”